Feedback plc AIM:FDBK
- Incorporated
- United Kingdom
- Chief executive
- Dr Tom Oakley
- Employees
- 29
- Reports in
- GBP
- Companies House
- 00598696
Read straight from the annual reports
6.4p at close on 5 Oct 2026 · 11 reported years, 2015–2025
| Line | FY201505/15 | FY201605/16 | FY201705/17 | FY201805/18 | FY201905/19 | FY202005/20 | FY202105/21 | FY202205/22 | FY202305/23 | FY202405/24 | FY202505/25 | FY2026unreported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Gross profit | ||||||||||||
| Operating profit | ||||||||||||
| Exceptional items | — | — | — | — | — | — | — | — | — | — | ||
| Net finance cost | ||||||||||||
| Profit before tax | ||||||||||||
| Tax charge | ||||||||||||
| Profit for the year | ||||||||||||
| EBITDA | ||||||||||||
| Basic EPS | ||||||||||||
| Diluted EPS | ||||||||||||
| Dividend per share | — | — | — | — | — | — | — | — | — | — |
GBP millions, negatives in brackets. Per-share lines in pence, share counts in millions. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated. The share price above is drawn to the same columns: each close sits over the financial year it fell in.
11 years, at a glance
Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Bleepa platform licences to NHS customers
Bleepa contributed 90% of sales (2024: 87%); 2025 external revenue includes Bleepa £794,440, Image Engineering licence fees £57,545 and legacy Cadran PACS £33,638.
page 18Queen Victoria Hospital (QVH) contract
QVH converted to a full contract at a higher contract value; £495k digital infrastructure contract awarded to QVH in the year.
page 5Gross margin decline on lower revenue
Gross margin fell to 88% (2024: 93%), driven by the fall in revenue.
page 18Operating expense growth
Operating expenses rose 7% to £5.15m on headcount growth, cost-of-living pay rises, a £0.22m share-based payment charge (including a £0.07m one-off accelerated charge) and higher amortisation (£1.15m). Partly offset by lower advertising and marketing spend.
page 18Improving our revenue performance remains our greatest challenge and focus. Trading conditions over the past six months have been the toughest the CEO has known, with NHS restructuring delaying decision-making since March 2025.
page 17Post period, the company curtailed activities in India for the time being, to extend its cash runway.
page 17No dividend was declared in FY2025 (2024: nil). No dividend policy is stated; capital management objectives include the possibility to vary dividend payments but none is proposed.
page 51Unmodified opinion from Price Bailey LLP dated 16 September 2025 (senior statutory auditor Andrew Booth). The auditor reported no material uncertainty on going concern; directors' forecasts run to 30 September 2026 with downside scenarios and cash of £5,949,757 at 31 May 2025 sufficient to early CY2027. Five key audit matters: revenue recognition; capitalised development costs; intangible valuation and impairment; investments in subsidiaries impairment; share option valuation. Materiality £292,000 (group), performance materiality £175,000.
page 57- Product development: products may cost more or take longer to develop, and market size may be smaller than expected, requiring additional financingp.20
- Competition from better-resourced competitors and new technologies that could make in-development products obsolete and cause pricing pressurep.20
- Over-dependence on a single customer (the NHS): changes to NHS structure and procurement could reduce revenue or delay it, and the company may not be included in future frameworksp.21
- Cyber security threats leading to IT failure, data loss or GDPR finesp.21
Read from C000455-AR-2025-ch.
10 annual reports read, FY2016 to FY2025
Open a year to see what its report said. Every line in it carries the page it was read from.
Sources: Companies House (10)
FY2026Next report expected 23 Sept 2026